Provenge is een nieuw immuuntherapeutisch middel tegen prostaatkanker.

18 september 2017: Lees ook dit artikel: https://kanker-actueel.nl/NL/immuuntherapie-met-provenge-spirutacel-t-geeft-betere-resultaten-op-overall-overleving-bij-gevorderde-prostaatkanker-als-deze-gevolgd-wordt-door-dendritische-celtherapie.html

Hier enkele studies en artikelen over Provenge - Sipuleucel-T, een immuuntherapeutisch middel tegen hormoonresistente prostaatkanker bij elkaar gezet.
Vanaf 25 september 2012 is het ook voor mannen met prostaatkanker uit  Nederland en België mogeljik om in te schrijven voor een studie met Provenge - Sipuleucel-T. Vraag hiernaar bij uw oncoloog of uroloog. Deze moet de aanvraag doen. De studie beschrijving staat in het Europese trialregister: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001192-39/NL

In Nederland wordt Provenge gegeven via een zogeheten dendritische cel-transferese bij immuuntherapie: http://www.umcn.nl/Informatiefolders/4511-Dendritische_celaferese_-i.pdf
 
Inlichtingen voor Provenge studie zijn te verkrijgen bij:

claudia.schwarz@assigngroup.com Tel: 00431403 38 0524

Wie komen daarvoor in aanmerking?
1 Written informed consent obtained prior to the initiation of study procedures.
2 Males, age ≥ 18 years at time of registration.
3 Histologically documented adenocarcinoma of the prostate.
4 Metastatic disease as evidenced by soft tissue and/or bony metastases on bone scan and/or computed tomography (CT) scan of the abdomen and pelvis at any time prior to registration.
5 Castrate resistant prostate cancer. Subjects must have current or historical evidence of disease progression concomitant with surgical or medical castration, as demonstrated by PSA progression OR progression of measurable disease OR progression of non-measurable disease.
6 Serum PSA ≥ 5.0 ng/mL.
7 Castration levels of testosterone (≤ 50 ng/dL; ≤ 1.74 nmol/L) achieved via medical or surgical castration.
8 ECOG performance status ≤ 1 (see Appendix 1).
9 Adequate hematologic, renal, and liver function.
10 Negative serology tests indicating no active infection with human immunodeficiency virus types 1 and 2 (HIV-1/2), human T cell lymphotropic virus types 1 and 2 (HTLV-I/II), and Hepatitis B and C viruses.
 
En wie worden uitgesloten?

1 The presence of known brain metastases. In the case of suspected or questionable findings, the Investigator must address each finding in the subject’s medical record prior to registration.
2 A requirement for systemic immunosuppressive therapy for any reason.
3 Treatment with any investigational vaccine within 2 years prior to registration.
4 Any previous treatment with sipuleucel T.
5 Any previous treatment with ipilimumab (Yervoy™, MDX-010, or MDX-101) or denosumab (Xgeva™).
6 Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography > 50%), or spinal cord compression.
7 Subject with known malignancies other than prostate cancer that are likely to require treatment within 6 months of registration.
8 A history of allergic reactions attributed to compounds of similar chemical or biologic composition to sipuleucel T or GM-CSF.
9 More than 2 chemotherapy regimens at any time prior to registration.
10 Treatment with chemotherapy within 90 days of registration.
11 Received granulocyte colony-stimulating factor (G-CSF) or GM-CSF within 90 days prior to registration.
12 Treatment with any of the following medications or interventions within 28 days of registration:
• Systemic corticosteroids.
• Non-steroidal anti-androgens (e.g., bicalutamide, flutamide, or nilutamide).
• External beam radiation therapy or major surgery requiring general anesthetic.
• Any other systemic therapy for prostate cancer including secondary hormonal therapies, such as megestrol acetate (Megace®), diethylstilbestrol (DES), and ketoconazole. Medical castration therapy is not exclusionary.
• Immunosuppressive therapy.
• Treatment with any other investigational product.
13 Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5°F or 38.1°C) within 7 days prior to registration.
14 Any medical intervention or other condition which, in the opinion of the Investigator or the Dendreon Medical Monitor, could compromise adherence with study requirements or otherwise compromise the study’s objectives.

 


Plaats een reactie ...

Reageer op "Provenge een immuuntherapie met dendritische cellen bij prostaatkanker: een aantal artikelen bij elkaar gezet"


Gerelateerde artikelen
 

Gerelateerde artikelen

immuuntherapie met Provenge >> Provenge, het eerste immuuntherapeutische >> Provenge - Sipuleucel-T, vaccinatie >> Het vaccin Provenge zorgt >> Provenge als immuuntherapie >> Provenge,- Sipuleucel-T, het >> Driejaars meting van fase >> Dubbelblinde gerandomiseerde >> Immuuntherapeutische aanpak, >>